证券记录 · 已归档季度
GRAL
GRAIL Inc. · Healthcare · Medical - Diagnostics & Research
13被追踪持有人
+1Δ持有人
6.08M持有股份
$155.14M报告持仓市值
+2新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 +8.3% ·
股份流向 +14.4% ·
净新建仓位 +7.7%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 111 | +3 | 19.70M | $1.34B | +13 | −9 |
| Q1 2026 | 110 | -6 | 18.56M | $959.35M | +4 | −11 |
| Q4 2025 | 117 | +2 | 17.78M | $1.52B | +3 | — |
| Q3 2025 | 18 | +1 | 10.99M | $649.07M | +2 | −2 |
| Q2 2025 | 15 | -1 | 10.50M | $537.63M | +1 | −2 |
| Q1 2025 | 13 | +1 | 6.08M | $155.14M | +2 | −1 |
| Q4 2024 | 12 | +2 | 5.32M | $94.90M | +3 | −1 |
| Q3 2024 | 9 | -6 | 3.74M | $51.49M | — | −6 |
| Q2 2024 | 15 | — | 4.39M | $67.54M | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 2.05M | -1.3% | $52.40M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | AQR Capital Management ✦ | 1.34M | +61.0% | $33.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | AQR Capital Management ✦ | 1.34M | +61.0% | $33.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | AQR Capital Management ✦ | 1.34M | +61.0% | $33.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 1.34M | +61.0% | $33.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 1.34M | +61.0% | $33.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | State Street Global Advisors ✦ (被动) | 1.27M | +11.6% | $32.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 472.44K | +6.5% | $12.07M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Geode Capital Management ✦ (被动) | 472.44K | +6.5% | $12.07M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 268.28K | 新增 | $6.85M | 0.0% | New | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 266.09K | +175.4% | $6.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 152.93K | -45.9% | $3.91M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Millennium Management ✦ | 151.56K | -48.7% | $3.87M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | GAMCO Investors ✦ | 28.00K | +8.1% | $715,120 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 25.41K | +3.6% | $649,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Wellington Management ✦ | 21.61K | -5.5% | $551,919 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Norges Bank ✦ (被动) | 21.60K | -67.4% | $551,613 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Marshall Wace ✦ | 16.18K | 新增 | $413,288 | 0.0% | New | 1 | SEC ↗ |
| 19 | Marshall Wace ✦ | 16.18K | 新增 | $413,288 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| D. E. Shaw & Co. | $6.85M | 0.0% |
| Marshall Wace | $413,288 | 0.0% |
| Marshall Wace | $413,288 | 0.0% |
已清仓
| Arrowstreet Capital | $205,293 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1 持有人, 9.40K 股份, $485 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据